In their latest publication in Neurology, Bart van de Warrenburg and Nienke van Os have identified clinically recognizable subtypes within milder forms of ataxia telangiectasia.Together with Michèl Willemsen and others, Nienke van Os and Bart van de Warrenburg were able to study own and previously reported patients with milder forms of ataxia telangiectasia (AT). AT is a severe multisystem disease that leads to various neurological deficits, typically ataxia and other movement disorders, as well as to systemic complications such as malignancies and infections. In addition to the classic, early-onset, severely progressive disease, there are patients who present with milder forms of AT. They have for example a later age at onset, slower progression, or a different neurological phenotype. These milder forms are, however, more difficult to recognize and this causes diagnostic delay. As patients with these milder forms are also prone to develop malignancies, such a delay may have serious consequences. By carefully studying the data of a large cohort of mild AT patients, the researchers discovered six discernible trajectories of neurological manifestations in this cohort. This knowledge will help earlier recognition and timely diagnosis of patients with this severe condition.
Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia.
Van Os NJH, Hensiek A, van Gaalen J, Taylor AMR, van Deuren M, Weemaes CMR, Willemsen MAAP, van de Warrenburg BPC.
Related news items
Lowering cholesterol is not enough to reduce hyperactivity of the immune system14 June 2019
In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provides a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.read more
A personal touch of Johan van der Vlag13 June 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Johan van der Vlag.read more
Peter van der Kraan new theme leader Inflammatory diseases13 June 2019
It is our pleasure to introduce Peter van der Kraan from the Dept. of Rheumatology, as the new leader of our theme Inflammatory diseases. As such he will be the successor of Irma Joosten who has done an outstanding job in the last years as theme leader, for which we thank her wholeheartedly.read more
Intake of a reduced dose of pazopanib with food the effect on pharmacokinetics, patient safety and preference13 June 2019
In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food.read more